Dupilumab-Associated Cutaneous Adverse Events Among Adult Patients With Atopic Dermatitis: A Retrospective Study

This retrospective study analyzed cutaneous adverse events (cAEs) in 916 adult patients treated with dupilumab for atopic dermatitis at the University Federico II of Naples. The study found that 16.15% of patients experienced cAEs, including facial redness (8.95%), psoriasis (4.25%), alopecia areata (1.2%), skin peeling (1.2%), parapsoriasis (0.32%), and vitiligo (0.21%). Despite these events, most were mild and did not necessitate discontinuation of the treatment. Only 3.38% of patients stopped using dupilumab due to cAEs. These findings helped dermatologists better understand the side effects of dupilumab, aiding in improved treatment planning.